SC79

Catalog No.S7863

SC79 Chemical Structure

Molecular Weight(MW): 364.78

SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

Size Price Stock Quantity  
USD 117 In stock
USD 347 In stock
USD 697 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 22 Publications

5 Customer Reviews

  • Cells with OGN over-expression were challenged with EGF (100 ng/mL) and pretreated with SC79 (constitutive Akt activator) for 24 h. Western blotting with the significantly altered markers was performed.

    J Exp Clin Cancer Res, 2018, 37(1):41. SC79 purchased from Selleck.

    U251 cells were treated with PAMK-2206-2HCl or SC79 for 24 h. The expression of FoxM1 and MYBL2 were detected by western blotting.

    J Exp Clin Cancer Res, 2017, 36(1):105. SC79 purchased from Selleck.

  • cells with OGN over-expression were challenged with EGF (100 ng/ml) and pretreated with SC79 (constitutive Akt activator) for 24 h. Western blotting presented a significant reduction in expression of HIF-1α and VEGF. Data were representative of three independent experiments with one-way ANOVA test.

    EBioMedicine, 2018, 34:35-45. SC79 purchased from Selleck.

    SC79 enhances fusion and myotube formation of L6 myoblasts through upregulation of Akt signaling. Immunofluorescence analysis of L6 myoblasts in the presence of 1 μM SC79 or MK2206 at 3, 5 and 7 days during myogenic differentiation. Staining for myosin heavy chain (MHC, green) marks differentiated cells. Nuclei were counterstained with DAPI (blue). Fusion index, myofiber diameter and number of nuclei per myofiber were measured at 3, 5 and 7 days after differentiation in the presence of 1 μM SC79 or MK2206. Scale bar, 50 μm. The data are presented as the mean ± SD. ⁎P < 0.05 versus blank controls from the same day. MHC, myosin heavy chain.

    Biochim Biophys Acta Mol Basis Dis, 2017, 1863(11):2848-2861. SC79 purchased from Selleck.

  • The molecular structure along with the molecular weight (MW) of SC79 were presented (A). ARPE-19 cells were treated with applied concentration of SC79 (0.1–10 μg/mL, or 2.74–27.41 μM) for 1 h, p-Akt (Ser-473) and Akt1 expression was tested by Western blots and was quantified (B) n = 4). ARPE-19 cells (C and D) primary murine RPE cells ("Primary RPE", (E)) or HLECs (F) pretreated with applied concentration of SC79 for 30 min, were subjected to UV radiation (30 mJ/cm2), cells were further cultured for 24 h, and cell viability was tested by MTT assay (C, E and F); Cell death was detected by trypan blue staining assay (D). "Ctrl" stands for untreated control group (Same for all figures). For each assay, n = 5. Experiments in this figure were repeated three times to insure consistency of results. *p < 0.05 vs. “Ctrl” group (C–F). **p < 0.05 vs. UV only group (C-F).

    Oncotarget, 2016, 7(37):60123-60132. SC79 purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.
Targets
Akt [1]
In vitro

SC79 suppresses PHAKTM-GFP plasma membrane translocation, and enhances phosphorylation of all three Akt isoforms in HEK293, HeLa, HL60, NB4, and HsSulton (B cells) cells. SC79 reduces neuronal excitotoxicity and prevents stroke-induced neuronal death. [1] SC79 restores proliferation of BRAT1 knockdown cells, and reduces the production of superoxide in mitochondria of MitoSox positive cells. [2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 M2\NU2Fxd3C2b4Ppd{Bie3OjeR?= MYC1JO69dW:uL1y= MojJV2M5OCCkbH;jb5Mhfmm2ZYjpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NUDMfnRjOzB5OUeyN|Y>
HeLa NFPMbGRHfW6ldHnvckBie3OjeR?= M3fj[oRm[3KnYYPl[EB1cGViboXtZoVzKG:oIHH1eI9xcGGpb4PvcYV{KGmwZIXj[YQh[nliSG\KMWUhcW5iY3XscJM> NGf3dlI{ODV|NECwNS=>
SH-SY5Y NE\odnRHfW6ldHnvckBie3OjeR?= MVexNEDPxE1? Mne1N|AhdWmw NXe1dFhteHKnLYTy[YF1dWWwdDD3bZRpKFOFN{mgLFExKM7:TTmgcIFz\2WueTDheJRmdnWjdHXkJGgzVzJvaX7keYNm\CC|dYL2bZZidCC{ZXT1Z5Rqd25? NXW1PJpQOjl3NkCwPVc>
Sertoli MlXZSpVv[3Srb36gZZN{[Xl? M{TQflUvPeLCidM1US=> NYOzXGN[OzBibXnu Mo\yeZAuemWpdXzheIUhfGinIGDGU3MucW6mdXPl[EBld3ewLYLl[5Vt[XSrb36gc4YheC2Da4SxJHQ{ODhiYX7kJJAuSWu2MTDTOFc{ MmjzNlg1OzlyNke=

... Click to View More Cell Line Experimental Data
In vivo In the permanent focal cerebral ischemia mouse model, SC79 (0.04 mg/g, i.p.) enables the cytosolic activation of Akt, and recapitulates the primary cellular function of Akt signaling, resulting in augmented neuronal survival. [1]

Protocol

Kinase Assay:

[1]
+ Expand

Cytosolic phosphorylation of Akt:

Hela cells are serum starved for 1 hr and treated with IGF (100ng/mL) or SC79 (4 μg/mL) for 30 minutes. Cells are lysed in Lysis buffer containing 250 mM Sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA supplemented with protease inhibitors. Cells are passed through 25G needle several times and kept on ice for 20 minutes. Total cell lysate is taken at this point. Cell lysates are centrifuged at 100,000g for 30 minutes. Supernatant is collected as the cytosolic fraction. Pellet is washed with lysis buffer and represents the membrane fraction. Total cell lysate, cytosolic and membrane fractions are resolved by SDS-PAGE and analyzed for phospho-Akt (S473), Total Akt, Tubulin (cytosolic marker) and Orai1 (membrane marker) by western blotting.
Cell Research:

[1]
+ Expand
  • Cell lines: HsSultan and NB4 cells
  • Concentrations: 8 μg/mL
  • Incubation Time: 24 h
  • Method:

    HsSultan or NB4 cells (2.5 × 105) are plated in a 24-well plate in 500 μL of phenol red-free RPMI medium supplemented with 10% FBS. After incubation for 24 hours, each compound (8 µg/mL) is added and cultured for overnight (16–20 h). Fifty microliters of MTT solution (5 mg/mL in PBS) are added to each well. Following 2 hrs incubation, the purple formazan crystals are dissolved by directly adding in 500 μL of isopropanol with 0.1 M HCl to each well. After clearing the cell debris by centrifugation, the absorbance is measured at a wavelength of 570 nm.


    (Only for Reference)
Animal Research:

[1]
+ Expand
  • Animal Models: Permanent focal cerebral ischemia mouse model
  • Formulation: DMSO
  • Dosages: 0.04 mg/g
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 72 mg/mL (197.37 mM)
Ethanol 72 mg/mL warmed (197.37 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+corn oil
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 364.78
Formula

C17H17ClN2O5
CAS No. 305834-79-1
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

Akt Signaling Pathway Map

Related Akt Products0

  • Afuresertib (GSK2110183) New

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148 New

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • TIC10(ONC201) New

    TIC10 inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.

  • MK-2206 2HCl

    MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

    Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

  • Capivasertib (AZD5363)

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

Tags: buy SC79 | SC79 supplier | purchase SC79 | SC79 cost | SC79 manufacturer | order SC79 | SC79 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID